Antex Biologics Inc., of Gaithersburg, Md., appointed Kyle Keese vice president, business development.
Arrow Therapeutics Ltd., of London, added Sue Grieve as director of preclinical research and development.
Axiom Biotechnologies Inc., of San Diego, added Michael Kozlowski as chief operating officer, named Damien Dunnington vice president of discovery research and appointed Steven Brown director of molecular pharmacology.
Axonyx Inc., of New York, appointed Gosse Bruinsma chief operating officer.
Beckman Coulter Inc., of Fullerton, Calif., formed three divisions and named a president of each. George Bers will head the Life Science Research division, Edgar Vivanco will head the Specialty Testing division, and Albert Ziegler will head the Clinical Diagnostics division.
Bio-Technology General Corp., of Iselin, N.J., appointed Bernard Tyrrell senior vice president, worldwide marketing and sales.
Celera Genomics Inc., of Rockville, Md., appointed Lothar Krinke vice president, business development and strategic planning.
EluSys Therapeutics Inc., of Pine Brook, N.J., added Parag Saxena to its board.
Esperion Therapeutics Inc., of Ann Arbor, Mich., appointed Brian Krause vice president of development pharmacology.
Genomica Corp., of Boulder, Colo., appointed William Rich to its board.
ImaRx Therapeutics Inc., of Tucson, Ariz., added Nina Ossanna as senior director of business.
Immtech International Inc., of Vernon Hills, Ill., appointed Rostyk Mandzij laboratory manager.
Immusol Inc., of San Diego, added Niv Caviar as vice president, business development.
La Jolla Pharmaceutical Co., of San Diego, promoted Paul Jenn to vice president of operations and Theodora Reilly to vice president of human resources.
Metabasis Therapeutics Inc., of San Diego, added David Linemeyer as executive director of biological sciences responsible for both pharmacology and biochemistry research.
MitoKor, of San Diego, appointed Jerry Weisbach to its board and Barry Wolitzky vice president of preclinical research and development.
Neose Technologies Inc., of Horsham, Pa., formed an advisory board to support its GlycoAdvance business, comprised of Henrik Clausen, David James, Howard Levine, James Paulson, Harry Schachter and Pamela Stanley.
Nymox Pharmaceutical Corp., of Maywood, N.J., appointed Thomas Hudson and Joe Dylewski scientific consultants.
Onyx Pharmaceuticals Inc., of Richmond, Calif., appointed Scott Freeman vice president, clinical development.
Origenix Technologies Inc., of Montreal, elected Michael Atkin and Barry Markowsky to its board.